Puma Biotechnology shares jump 22.24% intraday after beating EPS by 278%.

Puma Biotechnology surged 22.24% intraday after reporting third-quarter 2025 earnings that beat estimates by 278%. The stock’s sharp rise coincided with the release of its 10-Q filing for the same period, which detailed the earnings outperformance. While the company’s Q3 results and subsequent investor reaction were likely driven by the strong earnings report, the exact nature of operational or financial metrics (e.g., revenue growth, royalty income) was not specified in the provided news summaries. The intraday rally suggests market participants reacted positively to the earnings surprise, aligning with typical investor behavior when companies exceed expectations in key financial metrics.